NCT00583544已完成1 期
A Double Blind, Sequential, Ascending Single Dose, Placebo-Controlled Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Study of TC-2216 in Healthy Young Male Volunteers.
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 72
- 试验地点
- 1
- 主要终点
- hematology, biochemistry, urine analysis, vital sign, ECG, adverse events.
研究概览
简要总结
Targacept, Inc. is studying TC-2216 for a potential role in the treatment of central nervous system (CNS) neurobiological disorders in anticipation of seeking an indication in depression and/or anxiety.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 40 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Male subjects aged 18-40 years old (both ages included).
- •Subjects must be in good health as determined by their medical history, physical examination, psychological examination, ECG, vital signs, standard EEG and laboratory tests. A volunteer with a clinical abnormality may be included only if the Investigator or his designee considers that the abnormality will not introduce additional risk factor for the subject's health, or interfere with the study objectives.
- •Subjects with a body mass index within the range 18-29 kg/m2 and a weight within the range of 60-90 kg.
- •Non-smoker subjects (a cotinine test will be performed at screening and Day -1
- •Subjects must be able to refrain from consuming xanthine containing beverages, and must refrain from intensive physical exercise during the study conduct (until the end of study visit).
- •Subjects must have signed an informed consent form indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study and comply with the study procedures and restrictions.
- •Subjects must be affiliated with, or a beneficiary of, a French social security system.
排除标准
- •Potential subjects who meet any of the following criteria will be excluded from participating in the study:
- •Any clinically relevant acute or chronic diseases which could interfere with the subjects safety during the trial, or expose them to undue risk, or which could interfere with the study objectives.
- •History or presence of gastrointestinal, hepatic, or renal disease or other condition known to interfere with the absorption, distribution, metabolism or excretion of drugs.
- •Any history of drug or other significant allergy.
- •Likely to need any treatment (including dental care) during the study period.
- •Donation of one or more units of blood within 90 days prior to the screening.
- •Use of any prescription or over-the-counter medication within 14 days prior to admission on Day-1 (not including paracetamol in the range of 1gr/day). In addition any medications with central effects are prohibited for a period equal to 5 x half-life prior to admission (Day-1), should this period be longer than 14 days.
- •Alcohol consumption > 40 g alcohol/day (1 glass (25 cl) of beer with 3° of alcohol = 7.5 g, or 1 glass (25 cl) of beer with 6° of alcohol = 15 g, or 1 glass (12.5 cl) of wine with 10° of alcohol = 12 g, or 1 glass (4cl) of aperitif with 42° of alcohol = 17 g).
- •Positive alcotest at screening and Day -1 .
- •Positive test result on hepatitis B surface antigen, hepatitis C antibody.
- •Positive test result on HIV 1 and 2 serology.
- •Excessive daily consumption of xanthines containing drinks (i.e > 500 mg/day of caffeine).
研究组 & 干预措施
1
Placebo Comparator
干预措施: TC-2216 (Drug)
2
Experimental
干预措施: TC-2216 (Drug)
结局指标
主要结局
hematology, biochemistry, urine analysis, vital sign, ECG, adverse events.
时间窗: 4 days
次要结局
- plasma and urine pharmacokinetics, Pharmaco EEG, Bond-Lader Visual Analogue Scal(4 days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Thorough QT (TQT) Study of TD-4208 in Healthy SubjectsCardiac Repolarization in Healthy SubjectsNCT02820311Mylan Inc.48
进行中（未招募）
不适用
Digital Therapeutic for Depression After Head Injury in Current and Former US Military PersonnelDepressive SymptomsMild Traumatic Brain InjuryNCT05147506Henry M. Jackson Foundation for the Advancement of Military Medicine113
已完成
2 期
TD-1792 in Gram-positive Complicated Skin and Skin Structure InfectionStaphylococcal Skin InfectionNCT00442832Theravance Biopharma203
已完成
1 期
Safety & PK of Single Doses of MT1980Neuroinflammatory ResponseNCT05429840Monument Therapeutics Limited24
已完成
不适用
Transcranial Direct Current Stimulation (tDCS) in the Treatment of Major Depressive Disorder (MDD)Major Depressive DisorderNCT01078948Centre for Addiction and Mental Health24